Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

FCA launches probe into pure protection insurance market

(Sharecast News) - The Financial Conduct Authority announced on Friday that it is to launch an investigation into the pure protection insurance market amid concerns about how adviser commissions are affecting consumers. Pure protection insurance products paid out £4.85bn to consumers in 2023 to support families with financial commitments in the event of bereavement, illness and injury.

However, while the FCA has received relatively few complaints, it said that there are worries about whether the commissions used to sell the products are affecting the outcomes consumers receive and the products' value or design.

Friday's launch of a so-called Market Study followed an announcement in August, which revealed that the regulator was looking into the sector.

The FCA is examining four specific products in its study: term assurance, critical illness cover, income protection insurance and whole of life insurance.

Among other things, the regulator is looking into whether advisers are wrongfully encouraging consumers to switch deals unnecessarily, and if premiums are being hiked so that insurers can pay higher commissions to intermediary parties.

"Consumers rely on pure protection to provide an important safety net, often when they are at their most vulnerable be it through bereavement, illness, or injury. We are determined to ensure the market is working well and delivers good outcomes for consumers by testing it or suggesting improvements," said Sarah Pritchard, executive director of supervision, policy, competition and international at the FCA.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.